Multiple sclerosis in pregnancy: meeting the challenges


  • Bhupendra Chaudhary Department of Neurology, Jaswant Rai Super Speciality Hospital, Meerut, Uttar Pradesh, India
  • Rashmi Basvantsing Rajput Department of Obstetrics and Gynecology, Bharati Vidyapeeth Medical College and Research Centre, Pune, Maharashtra, India
  • Ansh Chaudhary Department of Medicine, Bharati Vidyapeeth Medical College and Research Centre, Pune, Maharashtra, India



Disease modifying drugs, Labour, Multiple sclerosis, Pregnancy, Relapse


Multiple sclerosis being a chronic, autoimmune inflammatory disease of central nervous system with its common and uncommon semiology has a predilection for women of child bearing age. The stressful period of pregnancy is further complicated with presence of multiple sclerosis. Overall multiple sclerosis has stabilising effect on pregnancy especially in its second and third trimester but adversely affects the post-partum period with increasing relapse rate. This is related with intense immune response triggered by marked changes in levels of circulating hormones. A better understanding of anti-natal, natal and post-partum effect of multiple sclerosis helps us to decide for institution or continuation of disease modifying drugs which are generally associated with favourable outcome.


Goodin DS. The epidemiology of multiple sclerosis: insights to a causal cascade. Handb Clin Neurol. 2016;138:173-206.

Buraga I, Popovici RE. Multiple sclerosis and pregnancy: current considerations. Sci World J. 2014;2014:513160.

Hellwig K, Haghikia A, Rockhoff M, Gold R. Multiple Sclerosis and pregnancy: experience from a nationwide database in Germany. Ther Adv Neuro. Disord. 2012;5:247-53.

Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T. Rate of pregnancy- related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis. Group. N Engl J Med. 1988;339:285-9.

Dahl J, Myhr KM, Daltveit AK, Hoff JM, Gilhus NE. Pregnancy, delivery, and birth outcome in women with multiple sclerosis. Neurol. 2005;65(12):1961-3.

Kelly VM, Nelson LM, Chakravarty EF. Obstetric outcomes in women with multiple sclerosis and epilepsy. Neurol. 2009;73:1831-6.

Pasto L, Portaccio E, Ghezzi A, Hakiki B, Giannini M, Razzoloni L, et al. Epidural analgesia and caesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study. BMC Neurol. 2012;12:165.

Langer- Gould A, Huang SM, Gupta R, Leimpeter AD, Greenwood E, Albers KB, et al. Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis. Arch Neurol. 2009;66:958-63.

Lu E, Dahlgren, L, Sadovnick A, Sayao A, Synne A, Tremlett H. Perinatal outcomes in women with multiple sclerosis exposed to disease-modifying drugs. Mult Scler. 2012;18:460-7.

Alroughani R, Altintas A, Al Jumah M, Sahraia M, Alsharoqi I, AITahan A et al. Pregnancy and the use of disease -modifying therapies in patients with multiple sclerosis: benefits versus risks. Mult Scler Int. 2016;2016:1034912.

Salminen HJ, Leggett H, Boggild M. Glatiramer acetate exposure in pregnancy: preliminary safety and childbirth outcomes. J Neurol. 2010;257:2020-3.

Amato MP, Portaccio E. Fertility, pregnancy and childbirth in patients with multiple sclerosis: impact of disease- modifying drugs. CNS Drugs. 2015;29:207-20.

Lu E, Wang BW, Guimond C, Synnes A, Sadovnick D, Tremlett H. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. Neurol. 2012;79:1130-5.

Achiron A, Chambers C, Fox EJ, Mc Combe P, Otero S, Margolin DH, et al. Pregnancy outcomes in patients with active RRMS who received alemtuzumab in the clinical development program. Multi Scleros J. 2015;21:581-2.






Short Communication